CareQuest Innovation Partners’ Post

The best way to help founders and CEOs right now is to partner with them to secure strong syndicates and close rounds.

Shared lab spaces are a great way to reduce costs and accelerate progress for biotech start-ups. These spaces provide a streamlined launchpad complete with benches and a diverse network of industry mentors. If you're interested in learning more about co-working labs and how they can benefit your biotech start-up, check out the link below. #biotech #coworkinglabs

Are you in the #biotech #startup environment? Do not miss out on this great HERAX and Danmarks Eksport - og Investeringsfond event and the opportunity to gain insights on the latest #Industry #Trends in R&D! #Lifescience #Funding #AI #ML #Siteportals #DecentralizedClinicalTrials #SAFe #Agile #EIFO

Unveiling the next presenter in our Innovation Showcase 2023 series: RevoNA Bio, a University of Portsmouth spin-out, with a novel, patented discovery platform that enables in silico RNA drug discovery affordably at scale. The platform creates cell-free RNA arrays which enable high-throughput, real-time evaluation of multiple sequences vs binding molecules. Through internal projects and strategic partnerships, RevoNA is amassing proprietary, high-quality datasets to create a best-in-class prediction engine. The company is actively seeking partnerships with Pharma, Biotech and leading research institutions interested in either discovering novel compounds or profiling existing molecules. Want to hear more from RevoNA's CEO, Dr Charlotte Henderson? Sign up to our virtual event, or if you’d like to join us in person, just follow the FAQ on the event page to request a place: https://rb.gy/m74oa #LifeSciences #Biotech #Entrepreneurs #Investors #Innovation #StartUps

💰BIO Roundup: Deal-Making Tips And Tricks • WHO SHOULD READ THIS? BD&L professionals in small companies looking for larger partners or investors. • WHAT IS IT? A round-up of insights gathered by Citeline News & Insights reporters from panel discussions and in exclusive interviews at the BIO International Conference on the subject of deal-making. • WHY IS IT IMPORTANT? Biotech companies are competing for the attention of potential partners to fund their R&D and help them achieve commercial success. This feature highlights key advice on decision-making, ranging from pipeline strategy to approaching international markets. Citeline Citeline Commercial #BIO2024

🔬 **Biotech Funding Insights!** While recent weeks have seen blockbuster funding rounds in the private biotech sector, a deeper look reveals a more nuanced picture. Notable fundings include a Flagship startup raising $273 million and an RNA company securing $200 million. However, despite these impressive numbers, biotech financing for 2023 seems to be aligning more with pre-pandemic norms rather than the boom witnessed during 2020 and 2021. Dive into the details and understand the current landscape of biotech investments in this enlightening article by Endpoints News. [Read more] #BiotechTrends #BiotechFunding #InvestmentInsights #BiotechStartups #HealthTech #BiotechResearch #VentureCapital #EndpointsNews @MaxGelman (https://lnkd.in/e3im7SHh)."

The resurgence in US biotech funding is a beacon of hope, not just for the industry, but for the global health ecosystem.🔬 At Adelphi Ventures, we believe that the right guidance can turn potential into reality. We're committed to nurturing early-stage biotech startups poised for market disruption. Let's innovate together and shape a healthier future. Reference: Labiotech - Will the US biotech funding surge trigger a renaissance in the global biotech industry? https://lnkd.in/egbvRwbC #BiotechBoom #EarlyStageInnovation #MarketDisruption #AdelphiVentures #HealthTech #StartupGrowth #InvestmentOpportunity #USBiotech #BioEcosystem #SustainableHealth #MedicalAdvancements #TechInvesting #LifeSciences #BiotechFunding #HealthcareInnovation #VentureCapital #Biomedical #GlobalHealthImpact #ScienceAndTechnology #FutureOfHealthcare

New: #biotech #IPOs have raised about $1.2 billion so far this year, the sector's fastest start since 2021. Gwendolyn Wu and I looked at what we've seen during this early surge, what's coming next, and how what’s happening in the public markets is affecting drug #startups. #biotechnology #biotechnologyindustry #iponews #venturecapital #drugdevelopment #drugdiscovery

#GateBiosciences, a #biotechnology startup located in #California, has secured $60 million in a series A fundraising round. Versant Ventures and a16z Bio + Health led the #funding effort, with participation from GV and ARCH Venture Partners. The money will be used by the business for both its operations and growth initiatives. #Molecular Gates is a new class of #medications being developed by Gate Bioscience, a preclinical biotech business led by CEO Jordi Mata-Fink. Its medicines are tiny compounds that work to treat illnesses by removing dangerous #extracellular proteins one at a time, within the cell. Before being secreted into the body, each extracellular protein—of which there are over 4,000—must cross a single channel within the cell. When Molecular Gates attach to this channel, a "gate" is created that #detects and prevents a particular protein that causes #disease from leaving the body. The protein is routed to be broken down by the cell's own #cleaning system rather than being secreted as it has nowhere else to go. Gate attempts to cure sufferers of the condition by removing the #toxic protein at its source. Gate Bioscience Versant Ventures ARCH Venture Partners Jordi Mata-Fink #gatebioscience #funding #startup

Reverse mergers are en vogue, and Frequency Therapeutics will join the bonanza, with #RNA editing startup Korro Bio, Inc. expected to take its spot on the Nasdaq in the fourth quarter. The all-stock business combination, disclosed before Friday’s opening bell, essentially caps Frequency’s nine-year regenerative medicine journey, based on work out of Bob Langer’s #MIT lab..... ...It’s now handing the keys to Korro, which will concurrently receive $117 million from a bevy of big-name biotech backers, traditional crossover players and hedge funds. All told the biotech will have $170 million to keep the R&D engine running into 2026. That will bankroll its first request for clinical trial clearance in the back half of 2024 and human data are expected about a year later... #clinicaltrials #RNA #RNAediting #reversemerger #startup #117m #biotech #biotechnology #biotechnologyindustry Nasdaq Surveyor Capital CORMORANT ASSET MANAGEMENT LLC Atlas Venture New Enterprise Associates (NEA) Platanus Ventures Qiming Venture Partners Fidelity Investments #financing #lifesciences #regenerativemedicine #advancedtherapies Ram Aiyar